Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity

International Journal of Cancer

Volumn 76, Issue 2, 1998, Pages 250-258

  Lespagnard, Laurence ^a   Mettens', Pascal ^c   Verheyden, Anne Marie ^c   Tasiaux, Nicole ^b   Thielemans, Kris ^a   Van Meirvenne, Sonja ^b   Geldhof, Anja ^c   De Baetselier, Patrick ^c   Urbain, Jacques ^a   Leo, Oberdan ^a   Moser, Muriel ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Baxter R and D Europe   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11 ANTIGEN; CD24 ANTIGEN; CD86 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; MASTOCYTOMA; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR RESISTANCE;

ANIMALS; BONE MARROW CELLS; CELL FUSION; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; MAST-CELL SARCOMA; MICE; MICE, INBRED CBA; MICE, INBRED DBA; PHENOTYPE; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032513539     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980413)76:2<250::AID-IJC13>3.0.CO;2-G     Document Type: Article

References (32)

1. BIANCHI, R., GROHMANN, U., BELLADONA, M.L., SILLA, S., FALLARIXO, R, AYROLDI, E., FIORETTI, M.C. and PUCCETTI, P., IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol.,151, 1589-1597 (1996).
2. BRICHARD, V.G., WARMER, G., VAN PEL, A., MORLINOHEM, G., LUCAS, S. and BOON, T., Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Europ. J. limnunol, 25, 664-671 (1995).
3. CAUX, C., DEZUTTER-DAMBUYANT, C., SCHMITT, D. and BANCHEREAU, J., GM-CSF and TNF-y cooperate in the generation of dendritic Langerhans cells. Nature (Lond.), 360, 258-261 (1992).
4. DE SMEDT, T., PAJAK, B., MURAILLE, E., LESPAGNARD, L., HEINEN, E., DE BAETSELIER, P., URBAIN, J., LEO, O. and MOSER, M., Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J. exp. Med., 184, 1413-1424 (1996).
5. FALLARINO, F., UYTTENHOVE, C., BOON, T. and GAJEWSKI, T.J., Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol., 156, 1095-1100 (1996).
6. + T cells control in vivo growth of P815 mastocytoma. Int. J. Cancer, 45, 757-762 (1990).
7. GAJEWSKI, T.F., FALLARINO, F., UYTTENHOVE, C. and BOON, T., Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor. Superiority of B7-1 over B7-2 for active tumor immunization. J. Imimmol, 156, 2909-2917 (1996).
8. GARRIGAN, K., MORONI-RAWSON, P., MCMURRAY, C., HERMANS, I., ABERNETHY, N., WATSON, J. and RONCHESE, F., Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood, 88, 3508-3510 (1996).
9. GELDHOF, A.B., RAES, G., BAKKUS, M., DEVOS, S., THIELEMANS, K. and DE BAETSELIER, P., Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res., 55, 2730-2733 (1995).
10. GONG, G., CHEN, D., KASIIIWABA, M. and KUFE, D., Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nature (Med.), 3,558-560 (19.97).
11. GROHMANN, U., BIANCHI, R., AYROLDI, E., BELLADONA, M.L., SURACE, D., FIORETTI, M.C. and PUCCETTI, P., A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. ImimmoL, 158, 3593-3602 (1997).
12. GROHMANN, U., BIANCHI, R., FIORETTI, M.C., FALLARINO, F., BINAOLIA, L., UYTTENHOVE, C., VAN PEL, A., BOON, T. and PUCCETTI, P., CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tunv or helper peptides in priming for skin test eactivity to a P815AB-related peptide. Enrop. J. Immunol., 25, 2797-2802 (1995).
13. Guo, Y, Wu, M., CHEN, H., WANG, X., Liu, G., Li, G., MA, J. and SY, M.S., Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science, 263,518-520 (1994).
14. HUANG, A.Y.C., GOLUMBEK, P., AlIMADZADEH, M., JAFFEE, E., PARDOLL, D. and LEVITSKY, H., Role of bone marrow-derived cells in presenting MHC Class I-restricted tumor antigens. Science, 264,961-965 (1994).
15. INABA, K., INABA, M., ROMANI, N., AYA, H., DEGUCHI, S., IKEHARA, S., MURAMATSU, S. and STEINMAN, R.M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176, 1693-1702(1992).
16. INABA, K. and 12 OTHERS, The tissue distribution of B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. exp. Med., 180, 1849-1860 (1994).
17. Kos, F.J. and ENGLEMAN, E.G., Immune regulation: a critical link between NK cells and CTLs. Immunol. Today, 17, 174-176 (1996).
18. KUROSAWA, S., HARADA, M., MATSUZAKI, G., SHINOMIYA, Y., TERAO, H., KoBAYASHi, N. and NOMOTO, K., Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology, 85,338-346 (1995).
19. LETHE, B., VAN DEN EYNDE, B., VAN PEL, A., CORRADIN, G. and BOON, T., Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Enrop. J. Immunol, 22, 2283-2288 (1992).
20. Liu, Y. and JANEWAY JR, C.A., Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. nat. Acad. Sci. (Wash.), 89,3845-3849 (1992).
21. Liu, Y, WENGER, R.H., ZHAO, M. and NIELSEN, P.J., Distinct costimulatory molecules are required for the induction of effector and memory cy totoxic T lymphocytes. J. exp. Med., 185, 251-262 (1997).
22. NAQUET, P., ELLIS, J., SINGII, B., HODGES, R.S. and DELOVITCH, T., Processing of insulin. I. Analysis of immunogenic peptides and processing requirements for insulin A loop-specific T cells. J. Immunol, 139, 3955-3963(1987).
23. ROMANI, N., KOIDE, S., CROWLEY, M., WITMER-PACK, M., LIVINGSTONE, A.M., FATHMAN, C.G., INABA, K. and STEINMAN, R.M., Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J. exp. Med., 169, 1169-1178 (1989).
24. SCHWARTZ, R.H., A Cell culture model for T lymphocyte clonal anergy. Science, 248, 1349-1356(1990).
25. STEINMAN, R. M., PACK, M. and INABA, K., Dendritic cells in the T-cell areas of lymphoid organs. Immunol. Rev., 156, 25-37 (1997).
26. THOMPSON, C.B., Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell. 81, 979-982 (1995).
27. UYTTENHOVE, C., MARYANSKI, J. and BOON, T., Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. exp. Med., 157, 1040-1052 (1983).
28. VAN DEN EYNDE, B. and VAN DER BRUGGEN, P., T cell defined tumor antigens. Curr. Opin. Immunol., 9, 684-693 (1997).
29. VAN DEN EYNDE, B., LETHE, B., VAN PEL, A., DE PLAEN, E. and BOON, T., The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. exp. Med., 173, 1373-1384 (1991).
30. YANG, G., MIZUNO, M.T., HELLSTRöM, K.E. and CHEN, L., B7-negative versus B7-positive P815 tumor. Differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol., 158, 851-858 (1997).
31. YOUNG, J.W. and INABA, K., Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. exp. Med., 183, 7-11 (1996).
32. ZORINA, T., MAYORDOMO, J.I., WATKINS, S., LOTZE, M.T., DELEO, A.B. and ILDSTAD, ST., Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J. Immunolher., 16, 247 (1994).